Sage Therapeutics (SAGE) confirmed that Biogen (BIIB) has submitted to the company an unsolicited, nonbinding proposal to acquire all of the outstanding shares of Sage Therapeutics not already owned by Biogen for $7.22 per share. Consistent with its fiduciary duties and in consultation with its independent financial and legal advisors, the Sage Board of Directors will carefully review and evaluate the proposal made by Biogen to determine the course of action that it believes is in the best interest of the company and all Sage shareholders.
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SAGE:
- Sage Therapeutics price target raised to $5 from $4 at RBC Capital
- Sage Therapeutics price target lowered to $9 from $26 at Piper Sandler
- Sage Therapeutics price target lowered to $6 from $10 at Stifel
- Sage Therapeutics price target lowered to $9 from $10 at TD Cowen
- Sage Therapeutics price target lowered to $4 from $7 at BofA